Inogen sells US oxygen-rental unit to Rotech for up to $24.8M
What's the deal? Inogen has completed the sale of its US oxygen-rental business to Rotech HealthcareDealroom has a profile for this one. Try Dealroom → for total estimated cash consideration of up to $24.8 million. The asset sale, which closed on November 2, 2026, is payable in six installments and includes a long-term supply agreement.
What changes? Rotech takes over the transferred rental patients and assets, while Inogen keeps reaching those patients through Rotech's national distribution network. For Inogen, the deal sheds a service operation to focus on developing and selling respiratory products.
Why now? The rental business generated $24.3 million in first-half 2026 revenue, down 9.8% year over year. The sale is one piece of a broader restructuring at the medical technology company.
The financials: Inogen reported third-quarter revenue of $77.2 million from continuing operations, down 2.4% from $79.1 million a year earlier. Its GAAP loss from continuing operations widened to $14.8 million, from $3.6 million in the prior-year period.
What's the endgame? Inogen is simplifying its commercial model under new president and chief executive officer Andy Reding, appointed this quarter. It also launched a cost-reduction program targeting about $20 million in annualised savings by the end of 2027.
"We remain focused on building a simpler, more focused company that can deliver sustainable, profitable growth," Reding said.
The signal: The price matters less as a headline deal than as a marker of Inogen's pivot from running oxygen rentals to selling respiratory devices. The open question is whether the leaner model and Rotech partnership can lift growth and profitability.
Read more: investor.inogen.com
Image credit: Generated with Gemini
